CODEX DNA INC (DNAY) Fundamental Analysis & Valuation

NASDAQ:DNAY • US1920031010

Current stock price

1.3 USD
+0.1 (+8.33%)
Last:

This DNAY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. DNAY Profitability Analysis

1.1 Basic Checks

  • DNAY had negative earnings in the past year.
  • DNAY had a negative operating cash flow in the past year.
DNAY Yearly Net Income VS EBIT VS OCF VS FCFDNAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 -10M -20M -30M

1.2 Ratios

  • DNAY has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DNAY Yearly ROA, ROE, ROICDNAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

  • DNAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNAY Yearly Profit, Operating, Gross MarginsDNAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. DNAY Health Analysis

2.1 Basic Checks

  • DNAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • DNAY has more shares outstanding than it did 1 year ago.
  • DNAY has a better debt/assets ratio than last year.
DNAY Yearly Shares OutstandingDNAY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 5M 10M 15M 20M 25M
DNAY Yearly Total Debt VS Total AssetsDNAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -2.00, we must say that DNAY is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -2.00, DNAY is not doing good in the industry: 83.08% of the companies in the same industry are doing better.
  • DNAY has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.
  • DNAY has a Debt to Equity ratio of 0.37. This is comparable to the rest of the industry: DNAY outperforms 41.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z -2
ROIC/WACCN/A
WACC10.64%
DNAY Yearly LT Debt VS Equity VS FCFDNAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 4.86 indicates that DNAY has no problem at all paying its short term obligations.
  • The Current ratio of DNAY (4.86) is comparable to the rest of the industry.
  • A Quick Ratio of 4.68 indicates that DNAY has no problem at all paying its short term obligations.
  • With a Quick ratio value of 4.68, DNAY perfoms like the industry average, outperforming 58.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.86
Quick Ratio 4.68
DNAY Yearly Current Assets VS Current LiabilitesDNAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. DNAY Growth Analysis

3.1 Past

  • The earnings per share for DNAY have decreased strongly by -63.94% in the last year.
  • The Revenue has grown by 112.52% in the past year. This is a very strong growth!
EPS 1Y (TTM)-63.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.53%
Revenue 1Y (TTM)112.52%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%139.59%

3.2 Future

  • Based on estimates for the next years, DNAY will show a small growth in Earnings Per Share. The EPS will grow by 0.26% on average per year.
  • Based on estimates for the next years, DNAY will show a very strong growth in Revenue. The Revenue will grow by 65.78% on average per year.
EPS Next Y-6.4%
EPS Next 2Y5.24%
EPS Next 3Y7.97%
EPS Next 5Y0.26%
Revenue Next Year106.09%
Revenue Next 2Y97.94%
Revenue Next 3Y85.04%
Revenue Next 5Y65.78%

3.3 Evolution

DNAY Yearly Revenue VS EstimatesDNAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
DNAY Yearly EPS VS EstimatesDNAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. DNAY Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DNAY. In the last year negative earnings were reported.
  • Also next year DNAY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNAY Price Earnings VS Forward Price EarningsDNAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNAY Per share dataDNAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.24%
EPS Next 3Y7.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DNAY Dividend Analysis

5.1 Amount

  • DNAY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

DNAY Fundamentals: All Metrics, Ratios and Statistics

CODEX DNA INC

NASDAQ:DNAY (1/3/2023, 8:00:01 PM)

1.3

+0.1 (+8.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-08
Earnings (Next)N/A
Inst Owners0.08%
Inst Owner Change0%
Ins Owners28.32%
Ins Owner Change0%
Market Cap38.38M
Revenue(TTM)21.04M
Net Income(TTM)-52.83M
Analysts84.44
Price Target6.63 (410%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.52%
Min EPS beat(2)4.82%
Max EPS beat(2)14.22%
EPS beat(4)2
Avg EPS beat(4)0.27%
Min EPS beat(4)-12.92%
Max EPS beat(4)14.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)24.03%
Min Revenue beat(2)23.47%
Max Revenue beat(2)24.59%
Revenue beat(4)3
Avg Revenue beat(4)9.32%
Min Revenue beat(4)-21.28%
Max Revenue beat(4)24.59%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.82
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 1.05
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-1.57
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.54
OCFYN/A
SpS0.71
BVpS1.81
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 349.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.86
Quick Ratio 4.68
Altman-Z -2
F-Score3
WACC10.64%
ROIC/WACCN/A
Cap/Depr(3y)78.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-63.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.53%
EPS Next Y-6.4%
EPS Next 2Y5.24%
EPS Next 3Y7.97%
EPS Next 5Y0.26%
Revenue 1Y (TTM)112.52%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%139.59%
Revenue Next Year106.09%
Revenue Next 2Y97.94%
Revenue Next 3Y85.04%
Revenue Next 5Y65.78%
EBIT growth 1Y-78.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.29%
EBIT Next 3Y-12.51%
EBIT Next 5Y-7.76%
FCF growth 1Y-147.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-138.59%
OCF growth 3YN/A
OCF growth 5YN/A

CODEX DNA INC / DNAY Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CODEX DNA INC (DNAY) stock?

ChartMill assigns a fundamental rating of 3 / 10 to DNAY.


What is the valuation status of CODEX DNA INC (DNAY) stock?

ChartMill assigns a valuation rating of 3 / 10 to CODEX DNA INC (DNAY). This can be considered as Overvalued.


Can you provide the profitability details for CODEX DNA INC?

CODEX DNA INC (DNAY) has a profitability rating of 1 / 10.


Can you provide the financial health for DNAY stock?

The financial health rating of CODEX DNA INC (DNAY) is 3 / 10.